PASG (34) INAB (34) ATYR (45) BCDA (38) ⌘ Pro Terminal →

Intensity Therapeutics Inc. (INTS) — RQD Stock Rating Cockpit

$3.40 +1.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.40

Intensity Therapeutics Inc. (INTS) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $10.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INTS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Intensity Therapeutics Inc. (NASDAQ: INTS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $3.40 (+1.80% 1D, market cap $10.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INTS ranks #566 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INTS compare to PASG and INAB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INTS carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PASG (Passage Bio Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.3M) and INAB (IN8bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.7M). Among the 5-stock peer group, INTS leads on earnings multiple (N/A) while INTS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INTS?

▼

Per INTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001567264), Intensity Therapeutics Inc. generated $0 in revenue, -$11.6M in net income, and -$9.2M in free cash flow against $14.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.40 (+0.13%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INTS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY INTS SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (28% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 45.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.31-0.6% Next Q

Q2 (-2Q)

Grade E$3.29-2.7% Next Q

Q3 (-1Q)

Grade E$3.20+6.2% Next Q

Current

Grade D-$3.40-7.6% Hist 90D α

Trajectory: E (31) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INTS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INTS currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.74) and Max Pain ($3.57) forces dealer call-delta covering toward $30.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INTS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INTS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

45.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $3$3.40H: $29

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on INTS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (35)

10/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like INTS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INTS)

✓Walkthrough of INTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.62%📐 HORIZONTAL RANGE

2026-11-02O $3.38H $3.40L $3.34C $3.40VOL 7.7K

RES: $5.40SUP: $2.81SMA50: $3.74SMA200: $5.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INTS Butterfly Map → + Track INTS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INTS)

Health Care Rank #566 of 1016 ⚔️ PASG vs INTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INTS vs. PASG, INAB, ATYR, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Intensity Therapeutics Inc. (INTS) ranks #566 by composite RQD confidence (39/100, grade D-) and #891 by equity capitalization ($10.9M). Within this direct 5-issuer industry benchmark cohort, INTS leads on earnings valuation at N/A trailing P/E, while INTS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATYR currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with INTS at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INTS ACTIVE Intensity Therapeutics Inc.	D-	39/100	—	—	-35.0%	+1.80%	$10.9M	Benchmark Subject
PASG Passage Bio Inc.	E	34/100	—	—	-35.0%	-1.99%	$11.3M	/pasg-vs-ints →
INAB IN8bio Inc.	E	34/100	—	—	-35.0%	-8.04%	$9.7M	/inab-vs-ints →
ATYR aTyr Pharma Inc.	D	45/100	—	—	-35.0%	-8.01%	$13.5M	/atyr-vs-ints →
BCDA BioCardia Inc.	D-	38/100	—	—	-35.0%	-7.02%	$14.0M	/bcda-vs-ints →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001567264

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Intensity Therapeutics Inc. (INTS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.6M, operating cash flow of -$9.2M, and free cash flow of -$9.2M (+39.3% YoY). On the balance sheet, INTS closed FY2025 with $14.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.6M	-$9.2M	-$9.2M	$14.1M	—
FY2024 (FY)	2024-12-31	$0	-$16.3M	-$15.2M	-$15.2M	$4.8M	—
FY2023 (FY)	2023-12-31	$0	-$10.5M	-$7.2M	-$7.2M	—	—

3. INTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INTS compare to PASG and INAB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INTS?

Where is INTS trading relative to its 50-day, 200-day, and 52-week technical levels?

INTS last traded at $3.40 (+1.80% on volume of 16,120 shares), positioning the stock -9.09% below its 50-day simple moving average ($3.74) and -34.49% below its 200-day simple moving average ($5.19). Across its 52-week range of $3.00 to $28.75, INTS sits at the 1.6% percentile with a 14-day RSI of 45.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.98 to $3.82).

INTS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell INTS stock right now?

Intensity Therapeutics Inc. (INTS) currently earns a Roarable Rating of D- (Sell — SELL) with 39/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is INTS's 12-month price target and RQD AI Jury consensus?

INTS's 12-month base price target is $3.11 (range $2.43 to $30.19), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: INTS RQD Cockpit INTS 12M Forecast INTS Earnings & Move INTS Dividends & DRIP INTS Insiders & 13F INTS Whale Options INTS Profit Sankey INTS News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

INTS — Intensity Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, INTS scores 39 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 8 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. For an investor, this indicates the business is not currently generating returns on capital or free cash flow to offset its losses.
Whale 13F Flow: 5 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is low, indicating limited institutional support in the source data.
Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider signaling.
Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. This is the strongest pillar, though still below midpoint.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. These metrics point to moderate financial stress.

Investment implications: the upside drivers in the source data are limited to the low-beta profile and the recent news flow. Valuation tradeoffs are significant because earnings-based multiples are not available in source data while the company reports net losses in each listed period. The rating's overall weakness suggests that any price recovery would need to be supported by improved cash generation or institutional and insider buying, neither of which the source data currently shows.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-12.0M	$-11.6M	N/A	$-9.2M	$11.9M	N/A
FY 2024	$0.0M	$-16.6M	$-16.3M	N/A	$-15.2M	$2.6M	N/A
FY 2023	$0.0M	$-8.3M	$-10.5M	N/A	$-7.2M	N/A	N/A

Per the SEC financials, the company reported operating and net losses in all three periods, with gross, operating, and net margins each at 0% per the market data. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Cash rose to $11.9M in FY 2025 from $2.6M in FY 2024 per the SEC financials, while debt is listed as N/A in each period.

Recent Catalysts & News Wire Analysis

Stock decline: A Stocktwits headline reports "Why Did INTS Stock Plummet 25% Today?" Per the news feed, this is a market-wire item, though the article body is not in source data.
Quarterly results timing: Per Yahoo Finance, the company will announce third quarter 2026 financial results on November 5, 2026.
Clinical data presentation: Per PR Newswire, the company will present INVINCIBLE-4 neoadjuvant triple-negative breast cancer study data for the first seven patients after INT230-6 treatment (Cohort A) at the European Society of Medical Oncology (ESMO) in an ePoster presentation.
Pre-market mention: Per Benzinga, INTS appeared among 12 Health Care stocks moving in a Friday pre-market session.
Analyst and estimates coverage: Per TradingView and Simply Wall St, estimates and forecast coverage exist for INTS, but no figures are included in source data.

Risk watch items: the reported 25% decline and the quarterly results date. Proprietary signals: none listed in the Butterfly Supply-Chain Graph.

Open Questions

What specific clinical or commercial milestones drive the company's cash burn and funding needs, and how long does current cash last at the FY 2025 operating loss rate?
What drove the reported 25% share price decline referenced in the Stocktwits headline?
What are the terms, size, and dilution implications of any financing that would be needed to fund continued operations?
What is the status and outcome of the INVINCIBLE-4 study data and the INT230-6 program?
Why is debt reported as N/A in every period while the forensic balance sheet pillar cites a Debt/Equity ratio of 0.5?

INTS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Intensity Therapeutics Inc. (INTS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INTS Debate Forum (3) ↓

🟡 MARKET WIRE Stocktwits • 11h ago

Why Did INTS Stock Plummet 25% Today?

Stocktwits report covering Intensity Therapeutics Inc. (INTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 14h ago

Intensity Therapeutics, Inc. Estimates – NASDAQ:INTS

TradingView report covering Intensity Therapeutics Inc. (INTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 17h ago

Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026

Yahoo Finance report covering Intensity Therapeutics Inc. (INTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 20h ago

Intensity Therapeutics (NasdaqCM:INTS) Stock Forecast & Analyst Predictions

Simply Wall St report covering Intensity Therapeutics Inc. (INTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE PR Newswire • 23h ago

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO)

PR Newswire report covering Intensity Therapeutics Inc. (INTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga report covering Intensity Therapeutics Inc. (INTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

INTS Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Costs Outpace Estimates - Analyst Drop Coverage

https://www.dars.gov.et/ report covering Intensity Therapeutics Inc. (INTS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 10d ago

Intensity Therapeutics To Present Data For First Seven Participants In Group A In INVINCIBLE-4 Trial In ePoster By The Swiss Cancer Institute At ESMO 2026 Virtual Congress Platform

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INTS Bull vs. Bear Conversation Board — What's Your Call at $3.40?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INTS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.94 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is INTS (D- • RQD 39/100) a Buy at $3.34?

Welcome to the INTS (Intensity Therapeutics Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.61 (-21.9%)

Spot @ $3.34

Pump the brakes on INTS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on INTS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Intensity Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.18 (+25.1%)

Spot @ $3.34

INTS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on INTS, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $3.34 (52-wk range $3.00 - $28.75), any beat on forward guidance forces shorts and underweight funds to chase.